Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • FAQ
  • Accessibility Statement

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Annual Meeting Materials
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • FBIOP Announcements
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Avenue Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

Nov 14, 2018

Mustang Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

Nov 13, 2018

InvaGen (a Cipla subsidiary) Announces Acquisition Agreement with Avenue Therapeutics for Specialty Hospital Business in the U.S.

Nov 13, 2018

Fortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

Nov 09, 2018

Checkpoint Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

Nov 02, 2018

Caelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentations at 60th American Society of Hematology Annual Meeting

Nov 02, 2018

Mustang Bio Announces Updates on CAR T Cell Therapy Clinical Trials with City of Hope

Oct 30, 2018

Checkpoint Therapeutics Appoints Christian Béchon to its Board of Directors

Oct 16, 2018

Mustang Bio Appoints Martina A. Sersch, M.D., Ph.D., as Chief Medical Officer

Oct 15, 2018

Mustang Bio to Present at 8th Annual Partnering Forum at Cell & Gene Meeting on the Mesa

Oct 01, 2018
RSS
  • Prev
    • 1...
    • 51
    • 52
    • 53
    • 54
    • 55
    • 56
    • 57
    • 58
    • 59
    • 60
    • ...71
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2025 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap